June 30, 2009 (Tokyo, Japan) — As expected, the US Food and Drug Administration has turned away the investigational diabetes drug alogliptin (Takeda Pharmaceutical) because of insufficient cardiovascular safety data [1]. The FDA decision will delay the drug’s possible launch by at least two years, according to company officials. Takeda received a “complete-response” letter on [...]